Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | STK4 | Q13043 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 8/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 6/20 | 0.36 |
| ▸ | CDK9 | P50750 | 5/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.36 |
| ▸ | CDK4 | P11802 | 3/20 | 0.36 |
| ▸ | CCND1 | P24385 | 3/20 | 0.36 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497199 | 0.85 | POLB (0.39) | CA9SRC | |
| SCHEMBL2498497 | 0.78 | SRC (0.56) | SRCABL1 | |
| SCHEMBL5997079 | 0.76 | LCK (0.44) | KDRBTKSRCABL1 | |
| SCHEMBL5998288 | 0.72 | LCK (0.56) | — | |
| SCHEMBL5997326 | 0.70 | KMT2A (0.46) | KDRABL1 | |
| SCHEMBL4265717 | 0.66 | SRC (0.73) | SRC | |
| SCHEMBL2497197 | 0.66 | SRC (0.53) | SRC | |
| SCHEMBL4275985 | 0.65 | SRC (0.69) | SRC | |
| SCHEMBL4266614 | 0.64 | SRC (0.70) | SRC | |
| SCHEMBL11274499 | 0.64 | CA2 (0.59) | CA1CA2CA9PLK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | CA1 4841/4885CA2 3366/4885CA9 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.